• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . The landscape of neutralizing antibodies against SARS-CoV-2 variants: Insights from a stratified vaccination cohort

tetano

Editor, Senior Moderator
Front Immunol


. 2025 Sep 26:16:1667392.
doi: 10.3389/fimmu.2025.1667392. eCollection 2025. The landscape of neutralizing antibodies against SARS-CoV-2 variants: Insights from a stratified vaccination cohort

Maria Julia Fialho[SUP] 1 [/SUP], Carlos José Ferreira da Silva[SUP] 1 2 [/SUP], Gabriel Brendo Alves Miranda[SUP] 1 [/SUP], Izadora Sthephanie da Silva Assis[SUP] 3 4 [/SUP], Adalgiza Mafra Moreno[SUP] 5 6 [/SUP], Paulo Henrique Moura[SUP] 6 [/SUP], Ana Carolina Proença da Fonseca[SUP] 1 3 4 7 [/SUP], Tamara Silva[SUP] 1 [/SUP], Sergian Vianna Cardozo[SUP] 1 8 [/SUP]



Affiliations
Abstract

Background: The COVID-19 pandemic has highlighted the crucial role of vaccines in preventing infection and reducing disease severity. However, emerging SARS-CoV-2 variants have posed challenges to vaccine-induced immunity.
Objective: To evaluate the immunological response and clinical characteristics of individuals with complete and incomplete COVID-19 vaccination schedules, with a focus on neutralizing antibody levels against SARS-CoV-2 variants.
Methods: A total of 245 participants were analyzed and stratified by complete and incomplete vaccination status. The complete vaccination was defined by 3 doses for <40 years or 4 doses for >40 years. Clinical data, serological responses, and neutralization levels against the Wuhan strain and the Delta and Omicron (BA.1, BA.2, BA.5) variants were evaluated.
Results: Among the participants, 71 (29%) had an incomplete vaccination schedule, and 174 (71%) had completed the recommended doses. Despite only 118 (48.2%) of participants reporting a prior positive COVID-19 test, 210 (85.7%) tested positive for anti-nucleocapsid antibodies, underscoring a high rate of undiagnosed or asymptomatic infections. Neutralization levels were reduced in incompletely vaccinated individuals, especially against the Omicron BA.2 variant (89%). A moderate-to-strong correlation was found between declining immunity and increasing time since last vaccination or infection. Older participants demonstrated lower neutralization rates against the Wuhan and Delta strains, and cross-reactivity was observed between Wuhan and Delta (r ≈ 0.7), as well as between Omicron BA.1 and BA.2. Finally, a strong negative association was observed between time since the last known SARS-CoV-2 infection and neutralization against Omicron BA.2, as well as moderate-to-strong negative correlations with Omicron BA.5 and BA.1.
Conclusion: COVID-19 vaccination is effective in eliciting protective immunity, although immune evasion by recent Omicron subvariants and waning immunity over time remain challenges. These findings support the need for updated booster strategies and continued public health efforts to ensure full vaccine coverage and long-term protection.

Keywords: COVID-19; SARS-COV-2 variants; immune response; neutralizing antibodies; vaccination.

 
Back
Top Bottom